



# Resource impact template

Resource impact

Published: 4 January 2023

Last updated: 22 August 2024

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for treating moderately to severely active ulcerative colitis:

- [Guselkumab for treating moderately to severely active ulcerative colitis](#) (2025) NICE technology appraisal guidance 1094
- [Risankizumab for treating moderately to severely active ulcerative colitis](#) (2024) NICE technology appraisal guidance 998
- [Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over](#) (2024) NICE technology appraisal guidance 956
- [Mirikizumab for treating moderately to severely active ulcerative colitis](#) (2023) NICE technology appraisal guidance 925
- [Upadacitinib for treating moderately to severely active ulcerative colitis](#) (2023) NICE technology appraisal guidance 856
- [Ozanimod for treating moderately to severely active ulcerative colitis](#) (2022) NICE technology appraisal guidance 828
- [Filgotinib for treating moderately to severely active ulcerative colitis](#) (2022) NICE technology appraisal guidance 792
- [Ustekinumab for treating moderately to severely active ulcerative colitis](#) (2020) NICE technology appraisal guidance 633
- [Tofacitinib for moderately to severely active ulcerative colitis](#) (2018) NICE technology appraisal guidance 547
- [Vedolizumab for treating moderately to severely active ulcerative colitis](#) (2015) NICE technology appraisal guidance 342
- [Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy](#) (2015) NICE technology appraisal guidance 329